• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Amarin Corporation plc: PharmaVitae Report Product Image

Amarin Corporation plc: PharmaVitae Report

  • Published: June 2012
  • Region: World
  • 31 Pages
  • Datamonitor

Analysis of Amarin's corporate history, corporate relationships, prospects to the end of the forecast period, and Datamonitor's evaluation of the company's strategy and key strengths, weaknesses, opportunities and threats.

This analysis evaluates the company’s strategy and key strengths, weaknesses, opportunities and threats, and provides an overview of the company’s historical and forecast financial performance. The report also gives an in-depth analysis of the company’s key prescription pharmaceutical product, and provides a forecast sales performance for this drug.

Scope

- Analysis of AMR101 and how it compares with Pronova/GlaxoSmithKline’s omega-3 fatty acid product Lovaza
- Discussion of the company's strategy, commercial relationships, and forthcoming catalysts
- Sales forecasts through to 2017
- Financial analysis of the company, including operating performance forecasts through to 2017

Highlights

- This report provides forecasts and analysis of Amarin's AMR101. AMR101 is currently being evaluated by the FDA for patients with very high triglycerides, with an expected PDUFA date of July 26, 2012. Amarin also READ MORE >

ABOUT THIS REPORT

- PharmaVitae Explorer database
- Chapter structure
- - Sales and product analysis
- - Financial analysis

- Data sourcing
- - Analyst consensus

EXECUTIVE SUMMARY

- Company introduction
- - Recent developments
- - Corporate relationships

- Strategic overview
- SWOT analysis?Strengths
- - Weaknesses
- - Opportunities
- - Threats

SALES AND PRODUCT ANALYSIS
- Sales overview
- Product analysis
- - Product sales

- AMR101?Hypertriglyceremia
- - Clinical trials
- - Factors affecting approval and use
- - Key forecast assumptions

FINANCIAL ANALYSIS

- Financial performance overview
- - Operating costs and profit analysis, 2006–11
- - Operating costs and profit analysis, 2010–16

APPENDIX
- References

- Exchange rates

TABLES

Table: Amarin catalyst timeline
Table: Amarin key product sales, by region ($m), 2012–17
Table: Amarin operating revenue/cost analysis ($m), 2006–11
Table: Amarin operating revenue/cost analysis ($m), 2012–17
Table: Exchange rates, 2011

FIGURES

Figure: PharmaVitae Explorer
Figure: Amarin prescription pharmaceutical performance, sales ($m) and growth rate (%), 2012–17
Figure: Amarin key product sales ($m), 2012–17
Figure: Amarin operating/cost performance ($m), 2006–17

Format Properties
Electronic (PDF) This company profile will be emailed to you. The company profile is sent in PDF format. This is a single user license, allowing one specific user access to the product.
Enterprisewide This company profile will be emailed to you. The company profile is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.
Note: Product cover images may vary from those shown
More

RELATED PRODUCTS